Published in Hum Nutr Clin Nutr on March 01, 1986
Oxidative stress: an important phenomenon with pathogenetic significance in the progression of acute pancreatitis. Gut (1998) 1.05
National statistics for diet, alcohol consumption, and chronic pancreatitis in England and Wales, 1960-88. Gut (1991) 1.02
Quality of life assessment in patients with chronic pancreatitis receiving antioxidant therapy. World J Gastroenterol (2010) 0.95
Fibrosis reduces severity of acute-on-chronic pancreatitis in humans. Gastroenterology (2013) 0.87
Occupational exposure to hydrocarbons and chronic pancreatitis: a case-referent study. Occup Environ Med (1994) 0.84
Pathogenesis and managenent of pain in chronic pancreatitis. World J Gastroenterol (2000) 0.79
Management of pain in chronic pancreatitis with emphasis on exogenous pancreatic enzymes. World J Gastrointest Pharmacol Ther (2016) 0.75
Fracture of the femur in old age: A two-centre study of associated clinical factors and the cause of the fall. Age Ageing (1978) 5.08
Quinolone antibiotics induce Shiga toxin-encoding bacteriophages, toxin production, and death in mice. J Infect Dis (2000) 4.24
The Aarhus statement: improving design and reporting of studies on early cancer diagnosis. Br J Cancer (2012) 3.80
Epidemiology of hip and knee pain and its impact on overall health status in older adults. Rheumatology (Oxford) (2004) 3.22
Reversal reactions in leprosy and their management. Lepr Rev (1991) 2.75
A systematic review of the literature exploring the role of primary care in genetic services. Fam Pract (1999) 2.62
Role for a phage promoter in Shiga toxin 2 expression from a pathogenic Escherichia coli strain. J Bacteriol (2001) 2.59
Psychosocial stress in pregnancy and its relation to low birth weight. Br Med J (Clin Res Ed) (1984) 2.28
Diagnostic strategies used in primary care. BMJ (2009) 2.23
Carbetocin versus oxytocin for the prevention of postpartum haemorrhage following caesarean section: the results of a double-blind randomised trial. BJOG (2010) 2.16
Regulation of the Shiga-like toxin II operon in Escherichia coli. Infect Immun (1996) 2.13
Reduced mortality compared with national averages following phacoemulsification cataract surgery: a retrospective observational study. Br J Ophthalmol (2008) 2.13
Purification of Shiga toxin and Shiga-like toxins I and II by receptor analog affinity chromatography with immobilized P1 glycoprotein and production of cross-reactive monoclonal antibodies. Infect Immun (1989) 2.12
Early discharge of patients with pulmonary embolism: a two-phase observational study. Eur Respir J (2007) 2.08
Prevalence and incidence of adults consulting for shoulder conditions in UK primary care; patterns of diagnosis and referral. Rheumatology (Oxford) (2005) 2.07
Evaluation of the premier EHEC assay for detection of Shiga toxin-producing Escherichia coli. J Clin Microbiol (1997) 1.97
Cytotoxic activities of Mannich bases of chalcones and related compounds. J Med Chem (1998) 1.74
The accuracy of general practitioner records of smoking and alcohol use: comparison with patient questionnaires. J Public Health Med (2000) 1.71
Shiga toxins induce, superinduce, and stabilize a variety of C-X-C chemokine mRNAs in intestinal epithelial cells, resulting in increased chemokine expression. Infect Immun (2001) 1.69
Widespread insecticide resistance in head lice to the over-the-counter pediculocides in England, and the emergence of carbaryl resistance. Br J Dermatol (2002) 1.67
Is microalbuminuria progressive? Arch Dis Child (1995) 1.66
Shiga toxins stimulate secretion of interleukin-8 from intestinal epithelial cells. Infect Immun (1999) 1.66
Prevalence, antibiotic susceptibility, and diversity of Escherichia coli O157:H7 isolates from a longitudinal study of beef cattle feedlots. Appl Environ Microbiol (2001) 1.60
Shortcomings of an automated assay for total antioxidant status in biological fluids. Clin Chem (1996) 1.54
Long-term results of Charnley low-friction arthroplasty in young patients. J Bone Joint Surg Br (1993) 1.54
Isogenic lysogens of diverse shiga toxin 2-encoding bacteriophages produce markedly different amounts of shiga toxin. Infect Immun (1999) 1.53
Mutation in the Jak kinase JH2 domain hyperactivates Drosophila and mammalian Jak-Stat pathways. Mol Cell Biol (1997) 1.52
Laserlight cues for gait freezing in Parkinson's disease: an open-label study. Parkinsonism Relat Disord (2010) 1.51
Shiga toxin translocation across intestinal epithelial cells is enhanced by neutrophil transmigration. Infect Immun (2001) 1.49
Abnormal drug metabolism in chronic pancreatitis. Treatment with antioxidants. Gastroenterology (1990) 1.48
Human neutrophils and their products induce Shiga toxin production by enterohemorrhagic Escherichia coli. Infect Immun (2001) 1.47
Mitomycin immunoblot colony assay for detection of Shiga-like toxin-producing Escherichia coli in fecal samples: comparison with DNA probes. J Clin Microbiol (1993) 1.43
Serum lipoprotein (a) in renal transplant recipients receiving cyclosporin monotherapy. Nephrol Dial Transplant (1993) 1.42
Successful treatment of a patient with chronic lymphocytic leukaemia (CLL) presenting with bony metastases with aggressive antibody and chemotherapy. Clin Lab Haematol (2005) 1.39
Biliary colic on abrupt withdrawal of octreotide. Lancet (1991) 1.38
Care of a child with hypospadias: ethical issues in practice. Br J Nurs (1992) 1.38
Acute transverse myelitis and Guillain-Barré overlap syndrome with serological evidence for mumps viraemia. Acta Neurol Scand (2001) 1.38
Identifying symptoms of ovarian cancer: a qualitative and quantitative study. BJOG (2008) 1.33
Pancreatitis--a retrospective study. Gut (1976) 1.33
Selective and sensitive method for PCR amplification of Escherichia coli 16S rRNA genes in soil. Appl Environ Microbiol (2000) 1.33
Antioxidant therapy for recurrent pancreatitis: placebo-controlled trial. Aliment Pharmacol Ther (1990) 1.32
Acetylcysteine to treat complications of pancreatitis. Lancet (1986) 1.32
Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol (1996) 1.31
Does your patient have pancreatic disease? J R Coll Physicians Lond (1982) 1.27
GT160-246, a toxin binding polymer for treatment of Clostridium difficile colitis. Antimicrob Agents Chemother (2001) 1.25
Clinical efficiency in a simulated emergency and relationship to team behaviours: a multisite cross-sectional study. BJOG (2011) 1.24
Development of isothiocyanate-enriched broccoli, and its enhanced ability to induce phase 2 detoxification enzymes in mammalian cells. Theor Appl Genet (2002) 1.24
Coexpression of the B subunit of Shiga toxin 1 and EaeA from enterohemorrhagic Escherichia coli in Vibrio cholerae vaccine strains. Infect Immun (1997) 1.22
Distinction between early and late ovarian hyperstimulation syndrome. Fertil Steril (2000) 1.21
Evaluation of the impact of two educational interventions on GP management of familial breast/ovarian cancer cases: a cluster randomised controlled trial. Br J Gen Pract (2001) 1.20
Overnight variations in cortisol, interleukin 6, tumour necrosis factor alpha and other cytokines in people with rheumatoid arthritis. Ann Rheum Dis (2008) 1.19
Antioxidant therapy for recurrent pancreatitis: biochemical profiles in a placebo-controlled trial. Aliment Pharmacol Ther (1992) 1.18
Shiga toxins 1 and 2 translocate differently across polarized intestinal epithelial cells. Infect Immun (1999) 1.18
Observations on the BT PABA/14C-PABA tubeless test of pancreatic function. Clin Chim Acta (1983) 1.17
Maturational regulation of globotriaosylceramide, the Shiga-like toxin 1 receptor, in cultured human gut epithelial cells. J Clin Invest (1995) 1.15
Prevention of coronary platelet aggregation with a phosphodiesterase inhibitor RX-RA 69. Thromb Res (1985) 1.14
Multivalent inhibition of AB(5) toxins. J Am Chem Soc (2001) 1.14
Supranormal 25-hydroxyvitamin D and subnormal 1,25-dihydroxyvitamin D: their role in X-linked hypophosphatemic rickets. Am J Dis Child (1980) 1.13
Pancreatic disease: a casualty of hepatic "detoxification"? Lancet (1983) 1.12
Pregnancy outcomes in women with or without placental malaria infection. Int J Gynaecol Obstet (2006) 1.11
Use of clinical risk factors to identify postmenopausal women with vertebral fractures. Osteoporos Int (2006) 1.11
Guidelines for referral to a regional genetics service: GPs respond by referring more appropriate cases. Fam Pract (2001) 1.11
Audit of diabetes care by caseload. Arch Dis Child (1997) 1.11
Vitamin C status in patients with acute pancreatitis. Br J Surg (1993) 1.09
Randomised controlled trial of combined paracetamol and ibuprofen for fever. Arch Dis Child (2006) 1.09
Random transposon mutagenesis of Campylobacter jejuni. Infect Immun (2000) 1.08
Relationship between pancreatic exocrine function and ductal morphology in chronic pancreatitis. Gastroenterology (1982) 1.07
A system for production and rapid purification of large amounts of the Shiga toxin/Shiga-like toxin I B subunit. Infect Immun (1990) 1.05
Evidence for early oxidative stress in acute pancreatitis. Clues for correction. Int J Pancreatol (1995) 1.05
Biological versus chronological ageing of oocytes, distinguishable by raised FSH levels in relation to the success of IVF treatment. Hum Reprod (2002) 1.04
Normalizing eating behavior reduces body weight and improves gastrointestinal hormonal secretion in obese adolescents. J Clin Endocrinol Metab (2011) 1.04
Molecular analysis of the erythropoietin receptor system in patients with polycythaemia vera. Br J Haematol (1994) 1.03
Computed tomography in pancreatic disease. Br J Radiol (1978) 1.03
Detection by ELISA of low numbers of Shiga-like toxin-producing Escherichia coli in mixed cultures after growth in the presence of mitomycin C. J Med Microbiol (1992) 1.03
Globotriaosylceramide, Gb3, is an alternative functional receptor for Shiga-like toxin 2e. Infect Immun (1995) 1.02
The risk of a subsequent cancer diagnosis after herpes zoster infection: primary care database study. Br J Cancer (2013) 1.02
Amphetamines in the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry (1975) 1.02
Shiga toxin: purification, structure, and function. Rev Infect Dis (1991) 1.01
Expanding the role of the family history in primary care. Br J Gen Pract (1999) 1.01
Dose-response comparison of ipratropium bromide from a metered-dose inhaler and by jet nebulisation. Thorax (1983) 1.00
Clinical factors associated with adverse outcome for babies weighing 2000 g or less at birth. Arch Dis Child (1988) 1.00
Micronutrient antioxidant status in patients with primary Raynaud's phenomenon and systemic sclerosis. J Rheumatol (1994) 0.99
An evaluation of commercial radioisotope methods for the determination of folate and vitamin B12. J Clin Pathol (1980) 0.99
More to teamwork than knowledge, skill and attitude. BJOG (2010) 0.99
Induction of drug-metabolizing enzymes in human pancreatic cancer and chronic pancreatitis. J Pathol (1993) 0.99
Sensorineural hearing loss and prematurity. Arch Dis Child Fetal Neonatal Ed (2000) 0.99
Type III procollagen peptide: a marker of disease activity and prognosis in primary biliary cirrhosis. Lancet (1988) 0.98
Triple versus dual therapy for eradicating Helicobacter pylori and preventing ulcer recurrence: a randomized, double-blind, multicenter study of lansoprazole, clarithromycin, and/or amoxicillin in different dosing regimens. Am J Gastroenterol (1998) 0.98
Responses of human intestinal microvascular endothelial cells to Shiga toxins 1 and 2 and pathogenesis of hemorrhagic colitis. Infect Immun (1999) 0.98
Lipid-peroxidation (free-radical-oxidation) products in bile from patients with pancreatic disease. Lancet (1983) 0.98
Heightened free radical activity in pancreatitis. Free Radic Biol Med (1990) 0.98
Circulating vitamin D metabolite concentrations in childhood renal diseases. Kidney Int (1982) 0.97
Comparison of the effects of Shiga-like toxin 1 on cytokine- and butyrate-treated human umbilical and saphenous vein endothelial cells. J Infect Dis (1996) 0.97
Discordant phenylketonuria phenotypes in one family: the relationship between genotype and clinical outcome is a function of multiple effects. J Med Genet (1995) 0.96
Relationship between PABA and Lundh tests: lack of influence of duodenal pH in vivo. Clin Chim Acta (1983) 0.96
Thrombotic thrombocytopenic purpura associated with Shiga toxins. Semin Hematol (1997) 0.96